Company:  HEDGEPATH PHARMACEUTICALS ... (HPPI)
Form Type:  8-K
Filing Date:  4/15/2019 
CIK:  0001042418 
Address:  324 SOUTH HYDE PARK AVENUE
SUITE 350
 
City, State, Zip:  TAMPA, Florida 33606 
Telephone:  (813) 864-2559 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$0.06  
Change: 
-0.0248 (-28.21%)  
Trade Time: 
Jun 26  
Market Cap: 
$23.34M
Trade HPPI now with 

© 2019  
Description of Business
We are a pharmaceutical development company that is seeking to discover, develop and ultimately commercialize innovative therapeutics for patients with certain cancers and non-cancerous proliferation disorders. We also have explored and expect to continue to explore acquiring or licensing other innovative preclinical and clinical stage therapeutics addressing unmet needs and orphan indications for the treatment of cancer and other diseases. Our current primary focus is on the development of therapies initially for prostate and also lung cancers in the United States utilizing SUBA®-Itraconazole, a patented, oral formulation of the currently marketed anti-fungal drug itraconazole to which we hold an exclusive U.S. license in the licensed field from our majority stockholder, Mayne Pharma Ventures Pty Ltd. (which we refer to herein collectively with its affiliates as Mayne Pharma).
Register and access this filing in:     
  FORM 8-K
    SECTION 8 OTHER EVENTS
      Item 8.01 Other Events
    SECTION 9 FINANCIAL STATEMENTS AND EXHIBITS
      Item 9.01. Financial Statements and Exhibits.
    SIGNATURES
  EXHIBIT 99.1